- Home
- CROX vs BIO Comparison
CROX vs BIO Comparison
Compare CROX & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CROX
- BIO
- Stock Information
- Founded
- CROX 1999
- BIO 1952
- Country
- CROX United States
- BIO United States
- Employees
- CROX N/A
- BIO N/A
- Industry
- CROX Shoe Manufacturing
- BIO Biotechnology: Laboratory Analytical Instruments
- Sector
- CROX Consumer Discretionary
- BIO Industrials
- Exchange
- CROX Nasdaq
- BIO Nasdaq
- Market Cap
- CROX 5.7B
- BIO 6.0B
- IPO Year
- CROX 2006
- BIO N/A
- Fundamental
- Price
- CROX $103.80
- BIO $257.04
- Analyst Decision
- CROX Buy
- BIO Strong Buy
- Analyst Count
- CROX 13
- BIO 4
- Target Price
- CROX $128.17
- BIO $324.25
- AVG Volume (30 Days)
- CROX 1.3M
- BIO 380.7K
- Earning Date
- CROX 08-07-2025
- BIO 07-31-2025
- Dividend Yield
- CROX N/A
- BIO N/A
- EPS Growth
- CROX 26.25
- BIO N/A
- EPS
- CROX 16.31
- BIO N/A
- Revenue
- CROX $4,100,808,000.00
- BIO $2,541,100,000.00
- Revenue This Year
- CROX $2.95
- BIO N/A
- Revenue Next Year
- CROX $2.84
- BIO $3.42
- P/E Ratio
- CROX $6.36
- BIO N/A
- Revenue Growth
- CROX 2.09
- BIO N/A
- 52 Week Low
- CROX $86.11
- BIO $211.43
- 52 Week High
- CROX $151.13
- BIO $387.99
- Technical
- Relative Strength Index (RSI)
- CROX 49.71
- BIO 65.41
- Support Level
- CROX $103.90
- BIO $245.87
- Resistance Level
- CROX $107.90
- BIO $264.68
- Average True Range (ATR)
- CROX 3.30
- BIO 7.34
- MACD
- CROX 0.43
- BIO 1.84
- Stochastic Oscillator
- CROX 58.46
- BIO 78.94
About CROX Crocs Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company are the United States and other Countries.
About BIO Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.